• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

5-氮杂胞苷治疗2型糖尿病患者的血糖失调:一例报告

Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report.

作者信息

Ponard Antoine, Ferreira-Maldent Nicole, Ertault Marjan, Delain Martine, Amraoui Kamel, Regina Sandra, Jonville-Béra Annie-Pierre, Hérault Olivier, Colombat Philippe, Gyan Emmanuel

机构信息

Service d'hématologie et thérapie cellulaire, Centre hospitalier universitaire, 2 boulevard Tonnellé, 37044, Tours, France.

Faculté de Médecine, Université François Rabelais, Tours, France.

出版信息

J Med Case Rep. 2018 Jul 3;12(1):199. doi: 10.1186/s13256-018-1690-3.

DOI:10.1186/s13256-018-1690-3
PMID:29966534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6029345/
Abstract

BACKGROUND

Diabetes and myelodysplastic syndrome are two conditions that may coexist in a single patient, since both diseases are prevalent in the elderly. The pathophysiology of myelodysplastic syndrome involves recurrent genetic mutations, especially in genes controlling epigenetic regulation. Although the pathophysiology of diabetes is not well understood, several studies suggest a role of epigenetics in type 2 diabetes.

CASE PRESENTATION

We report here for the first time the case of a 75-year-old Caucasian man who was treated for both diabetes and acute myeloid leukemia secondary to myelodysplastic syndrome, with a temporal association between glycemic dysregulation and the intake of 5-azacitidine. In fact, 2-3 days after starting each 7-day cycle of 5-azacitidine, he reported higher blood glucose levels, requiring an increased dose of self-administered insulin.

CONCLUSION

This observation could help to understand the pathophysiology of these two conditions and could encourage physicians to monitor blood glucose levels in patients under hypomethylating agent with a history of diabetes.

摘要

背景

糖尿病和骨髓增生异常综合征是两种可能在同一患者中并存的疾病,因为这两种疾病在老年人中都很常见。骨髓增生异常综合征的病理生理学涉及反复的基因突变,尤其是在控制表观遗传调控的基因中。虽然糖尿病的病理生理学尚未完全了解,但多项研究表明表观遗传学在2型糖尿病中起作用。

病例报告

我们在此首次报告一例75岁的白人男性病例,该患者因糖尿病和骨髓增生异常综合征继发的急性髓系白血病接受治疗,血糖失调与阿扎胞苷的摄入之间存在时间关联。事实上,在开始每7天一个周期的阿扎胞苷治疗后的2 - 3天,他报告血糖水平升高,需要增加自我注射胰岛素的剂量。

结论

这一观察结果有助于理解这两种疾病的病理生理学,并可能促使医生对有糖尿病史且正在接受低甲基化药物治疗的患者监测血糖水平。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/4059c3dadcf9/13256_2018_1690_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/859dc77e8464/13256_2018_1690_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/08185badc825/13256_2018_1690_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/41e2367cac8f/13256_2018_1690_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/4059c3dadcf9/13256_2018_1690_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/859dc77e8464/13256_2018_1690_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/08185badc825/13256_2018_1690_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/41e2367cac8f/13256_2018_1690_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ea/6029345/4059c3dadcf9/13256_2018_1690_Fig4_HTML.jpg

相似文献

1
Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report.5-氮杂胞苷治疗2型糖尿病患者的血糖失调:一例报告
J Med Case Rep. 2018 Jul 3;12(1):199. doi: 10.1186/s13256-018-1690-3.
2
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.高危骨髓增生异常综合征和继发性急性髓系白血病中对阿扎胞苷的反应与p53表达无关。
Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27.
3
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺:一项单臂1/2期研究。
Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.
4
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.高危骨髓增生异常综合征和继发性急性髓系白血病患者在诊断时的不同甲基化特征可预测阿扎胞苷的反应和更长的生存时间。
Clin Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y.
5
Safety and efficacy of azacitidine in myelodysplastic syndromes.阿扎胞苷在骨髓增生异常综合征中的安全性和有效性。
Drug Des Devel Ther. 2010 Sep 24;4:221-9. doi: 10.2147/dddt.s3143.
6
[Hypomethylating agents for the treatment of myelodysplastic syndromes].用于治疗骨髓增生异常综合征的低甲基化剂
Bull Cancer. 2011 Aug;98(8):927-34. doi: 10.1684/bdc.2011.1411.
7
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.靶向急性髓系白血病和骨髓增生异常综合征中的表观遗传途径:对去甲基化药物试验的系统评价
Clin Epigenetics. 2016 Jun 14;8:68. doi: 10.1186/s13148-016-0233-2. eCollection 2016.
8
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.阿扎胞苷:在骨髓增生异常综合征和急性髓系白血病中的综述。
Drugs. 2016 May;76(8):889-900. doi: 10.1007/s40265-016-0585-0.
9
Digging deep into "dirty" drugs - modulation of the methylation machinery.深入研究“脏”药物——甲基化机制的调控
Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8.
10
Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.骨髓增生异常综合征/急性髓系白血病患者接受去甲基化药物与组蛋白去乙酰化酶抑制剂联合治疗时Sweet综合征的非典型表现
Am J Hematol. 2009 Oct;84(10):688-9. doi: 10.1002/ajh.21510.

引用本文的文献

1
Epigenetic modifier alpha-ketoglutarate modulates aberrant gene body methylation and hydroxymethylation marks in diabetic heart.表观遗传修饰剂α-酮戊二酸调节糖尿病心脏中异常的基因体甲基化和羟甲基化标记。
Epigenetics Chromatin. 2023 Apr 27;16(1):12. doi: 10.1186/s13072-023-00489-4.
2
How to interact with medical terminologies? Formative usability evaluations comparing three approaches for supporting the use of MedDRA by pharmacovigilance specialists.如何与医学术语交互?三种方法比较,以支持药物警戒专家使用 MedDRA 的形成性可用性评估。
BMC Med Inform Decis Mak. 2020 Oct 9;20(1):261. doi: 10.1186/s12911-020-01280-1.
3

本文引用的文献

1
Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion.对2型糖尿病和非糖尿病供体的人类胰岛进行全基因组DNA甲基化分析,确定了影响胰岛素分泌的候选基因。
PLoS Genet. 2014 Mar 6;10(3):e1004160. doi: 10.1371/journal.pgen.1004160. eCollection 2014 Mar.
2
The role of mutations in epigenetic regulators in myeloid malignancies.基因突变在髓系恶性肿瘤中表观遗传学调控中的作用。
Nat Rev Cancer. 2012 Sep;12(9):599-612. doi: 10.1038/nrc3343. Epub 2012 Aug 17.
3
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.
Azacitidine-induced hyperglycaemia.
阿扎胞苷诱发的高血糖症。
BMJ Case Rep. 2019 Dec 1;12(11):e231903. doi: 10.1136/bcr-2019-231903.
地西他滨治疗骨髓增生异常综合征的 I/II 期研究:日本多中心研究。
Cancer Sci. 2012 Oct;103(10):1839-47. doi: 10.1111/j.1349-7006.2012.02386.x. Epub 2012 Sep 14.
4
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.一项关于5-氮杂胞苷联合苯丁酸钠用于难治性实体瘤患者的I期剂量探索研究。
Clin Cancer Res. 2009 Oct 1;15(19):6241-9. doi: 10.1158/1078-0432.CCR-09-0567. Epub 2009 Sep 29.
5
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.阿扎胞苷与传统治疗方案治疗高危骨髓增生异常综合征的疗效比较:一项随机、开放标签的III期研究。
Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.
6
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.全基因组关联分析确定2型糖尿病和甘油三酯水平的基因座。
Science. 2007 Jun 1;316(5829):1331-6. doi: 10.1126/science.1142358. Epub 2007 Apr 26.